Midelut (Bicalutamide)

Bicalutamide, the active ingredient in Midelut, is a nonsteroidal antiandrogen presented as an oral tablet for oral use. It is employed in the management of advanced prostate cancer, including locally advanced, metastatic and hormone‑sensitive disease in adult males.

GNH USA supplies Midelut as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU quality standards and providing the product to hospitals, oncology centres, pharmacies and clinics worldwide. The company ensures traceability, batch testing and secure logistics for each shipment. Customers benefit from dedicated technical support and regulatory documentation.

Bicalutamide is used as an androgen receptor antagonist in prostate cancer treatment.

Locally advanced prostate cancer: delays disease progression and may improve survival when combined with hormonal therapy. Metastatic prostate cancer: provides androgen blockade to control tumor growth in advanced disease. Hormone‑sensitive prostate cancer: enhances the effectiveness of castration therapy by blocking residual androgen activity. Adjuvant setting: used with luteinizing hormone‑releasing hormone analogues to achieve complete androgen blockade.

Bicalutamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient episodes of warmth, flushing and sweating that may occur at any time of day. - Gastrointestinal disturbances: nausea, abdominal discomfort, or diarrhea that can affect appetite. - Decreased libido: reduced sexual desire and possible erectile difficulties. - Fatigue: persistent tiredness that may interfere with daily activities.

Serious or Rare Side Effects: - Liver toxicity: significant elevation of liver enzymes, hepatitis or jaundice requiring monitoring. - Severe allergic reaction: rash, angioedema, or anaphylaxis that may need emergency treatment. - Pulmonary embolism: sudden shortness of breath, chest pain and possible cardiovascular compromise.

Before and during treatment, several safety measures should be observed. - Liver monitoring: perform baseline and periodic liver function tests during therapy. - Cardiovascular assessment: evaluate for history of thromboembolic disease before initiating treatment. - Hormone‑related effects: monitor for breast tenderness, gynecomastia or changes in sexual function. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception for women of childbearing potential. - Drug interactions: review concomitant medications for CYP3A4 inducers or anticoagulants. - Store at room temperature: keep below 25 °C in the original container, protect from moisture and light.

Bicalutamide can interact with several medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce bicalutamide exposure. - Warfarin: increased anticoagulant effect and INR elevation. - Certain anticonvulsants (e.g., phenobarbital): may lower plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP2C9 substrates (e.g., phenytoin, tolbutamide): possible altered levels. - Hormone replacement therapy: additive antiandrogen effects may increase side‑effects.